{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=49&state=Kentucky", "query": { "state": "Kentucky", "city": "Lexington", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 4521, "total_pages": 453, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=50&state=Kentucky&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=48&state=Kentucky&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T18:13:34.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02032823", "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1837, "start_date": "2014-04-22", "completion_date": "2029-05-28", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 368, "location_summary": "Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more", "locations": [ { "city": "Anchorage", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02032823" }, { "nct_id": "NCT05366751", "title": "A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Essential Tremor" ], "interventions": [ { "name": "SAGE-324", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sage Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 97, "start_date": "2022-06-03", "completion_date": "2024-09-10", "has_results": true, "last_update_posted_date": "2025-08-01", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 38, "location_summary": "Hoover, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Hoover", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05366751" }, { "nct_id": "NCT02100631", "title": "A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cholera" ], "interventions": [ { "name": "PXVX0200", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "46 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "46 Years to 64 Years" }, "enrollment_count": 398, "start_date": "2014-05", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 16, "location_summary": "Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "DeLand", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100631" }, { "nct_id": "NCT00108745", "title": "Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel Poliglumex", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 1157, "start_date": "2005-03-21", "completion_date": "2022-02-22", "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 315, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 228 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108745" }, { "nct_id": "NCT01570751", "title": "A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2012-04", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 45, "location_summary": "Mesa, Arizona • Fresno, California • Greenbrae, California + 39 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Ramon", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01570751" }, { "nct_id": "NCT00002602", "title": "Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "3D-CRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1084, "start_date": "1994-05", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 213, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002602" }, { "nct_id": "NCT06631053", "title": "FIT Exercise in 30d of ULLS-induced Muscle Disuse", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Muscle Atrophy", "Muscle Weakness" ], "interventions": [ { "name": "velocity-based FIT (VBFIT)", "type": "OTHER" }, { "name": "No Exercise", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Lance Bollinger", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "35 Years to 45 Years" }, "enrollment_count": 16, "start_date": "2024-10-23", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06631053" }, { "nct_id": "NCT05987241", "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Muscle Invasive Renal Pelvis Urothelial Carcinoma", "Muscle Invasive Ureter Urothelial Carcinoma", "Muscle Invasive Urethral Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "cfDNA or ctDNA Measurement", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 992, "start_date": "2024-02-02", "completion_date": "2030-09-02", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 495, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987241" }, { "nct_id": "NCT01458405", "title": "Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myocardial Infarction" ], "interventions": [ { "name": "CAP-1002 Allogeneic Cardiosphere-Derived Cells", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Capricor Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2012-11-13", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01458405" }, { "nct_id": "NCT05540522", "title": "A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Quadrivalent influenza modRNA vaccine", "type": "BIOLOGICAL" }, { "name": "Quadrivalent influenza vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45789, "start_date": "2022-09-12", "completion_date": "2024-03-12", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-10-30T18:13:34.397Z", "location_count": 263, "location_summary": "Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 192 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05540522" } ] }